DOCSLIB.ORG

Efficacy, Tolerability and Safety of Propiverine Hydrochloride In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efficacy, Tolerability and Safety of Propiverine Hydrochloride In 2009 THE AUTHORS . JOURNAL COMPILATION 2009 BJU INTERNATIONAL Reconstructive and Paediatric Urology EFFICACY, TOLERABILITY AND SAFETY OF PROPIVERINE VS OXYBUTYNIN IN CHILDREN WITH URGE INCONTINENCE FROM OAB ALLOUSSI ET AL. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study BJUIBJU INTERNATIONAL Schahnaz Alloussi, Gerd Mürtz1, Reinhard Braun2, Ulrich Gerhardt2, Martina Heinrich3, Eva Hellmis2, Werner Horn2, Daniela Marschall-Kehrel2, Kurt Niklas2, Michael Raabe2, Thomas Rößler2, Beatrix Seibt2, Stefan Siemer4, Daniela Schultz-Lampel5, Heiko Walter2, Burkhard Wiedeking2, Saladin Alloussi, Paul Bock6, Gerhard Strugala1 and Helmut Madersbacher7 Department of Urology and Paediatric Urology, Krankenhaus Neunkirchen GmbH, 1APOGEPHA Arzneimittel GmbH, Dresden, 2Urological Practice or General Practitioner (Leipzig, Dresden, Duisburg, Mönchengladbach, Stadtlengsfeld, Frankfurt/Main, Saarlouis, Rottweil, Zwickau, Grimmen and Essen), 3Dr von Haunersches Kinderspital, Kinderchirurgische Klinik, 4Department of Urology, University of Saarland, Homburg/Saar, 5Kontinenzzentrum Südwest, Klinikum Villingen-Schwenningen, Germany, 6IFAG Basel AG, Switzerland, and 7Department of Neuro- Urology, Landeskrankenhaus-Universitätskliniken-Innsbruck, Innsbruck, Austria Accepted for publication 13 August 2009 adverse events, adverse drug reactions events (3.9% vs 16.3%, odds ratio 4.813), Study Type – Therapy (observational caused by antimuscarinics and premature adverse drug reactions caused by propiverine cohort) treatment termination. or oxybutynin (2.8% vs 9.2%) and premature Level of Evidence 2b treatment termination due to adverse drug RESULTS reactions (1.6% vs 4.4%). OBJECTIVE At 16 study centres, 621 children aged To compare, in a retrospective observational 5–14 years with UI due to overactive bladder CONCLUSION cohort study, the efficacy, tolerability and were enrolled. After anticholinergic safety of propiverine and oxybutynin in treatment (437 propiverine, 184 oxybutynin) Propiverine and oxybutynin are effective in children with urge incontinence (UI) due to continence was achieved in 61.6% and children with UI due to overactive bladder. overactive bladder. 58.7% of the patients after 186 and Sufficient treatment periods of at least 2, 259 days, respectively. There were clinically preferably 3–4, months are the crucial PATIENTS AND METHODS relevant improvements in voiding frequency factors for a successful treatment. The across treatment groups. Daily doses of tolerability profile of propiverine is better Medical records were scrutinized for children propiverine were markedly below the than for oxybutynin. with UI. As a primary efficacy outcome recommendations (0.54 vs 0.8 mg/kg body variable the achievement of continence after weight), daily doses of oxybutynin were treatment with variable doses of propiverine according to the recommendations (0.31 vs KEYWORDS or oxybutynin was assessed. Weekly UI 0.2–0.4 mg/kg body weight) at treatment episodes and daily voiding frequency were initiation. There was a significantly more anticholinergics, children, overactive evaluated as secondary efficacy outcomes. favourable tolerability to propiverine than bladder, oxybutynin, propiverine, urinary Tolerability was evaluated by the rate of oxybutynin for the overall rate of adverse incontinence INTRODUCTION date, oxybutynin, propiverine, tolterodine and studies, despite enrolling many patients [1]. trospium chloride have been investigated, but For trospium chloride only one dose-finding Anticholinergics and behavioural to a very varied extent. Tolterodine was not study has been conducted so far [2]. The use interventions are the mainstays for treating confirmed to be effective in children with OAB of oxybutynin is primarily based on clinical children with an overactive bladder (OAB). To in two multinational, multicentre clinical experience in adults. Controlled clinical © 2009 THE AUTHORS 550 JOURNAL COMPILATION © 2009 BJU INTERNATIONAL | 106, 550–556 | doi:10.1111/j.1464-410X.2009.09129.x EFFICACY, TOLERABILITY AND SAFETY OF PROPIVERINE VS OXYBUTYNIN IN CHILDREN WITH UI FROM OAB studies in children [3] are rare, and clinical responsible for the conduct of the study. oxybutynin (two-sided test, α = 0.05). Based reports consistently show limited tolerability Altogether, 34 of 50 institutions initially on the above defined ‘success’ probabilities of [4]. Even for oxybutynin extended-release responding expressed principal interest in both treatment groups, the one-sided 97.5% only a few open-label trials with few patients study participation, whereof 16 across CI of the OR was calculated. Logistic have been conducted [5]. Nevertheless, Germany invested the required time to regression was used to determine the OR and despite these major disadvantages, participate. At these centres all medical to adjust the endpoint to baseline imbalances oxybutynin remains the most frequently records of children with the indication under and confounders. The critical value for prescribed anticholinergic worldwide in investigation were scrutinized and noninferiority of 14%, based on expert children. A more favourable tolerability chronologically enrolled during the period opinions, assuming a success-probability of and safety profile has been reported for 1998–2003. The following key inclusion 0.5 (50%) for the propiverine treatment, is propiverine [6], a compound with a dual mode criteria had to be fulfilled: (i) Urge equivalent to an OR of 0.563. These analyses of action, with anticholinergic and calcium- incontinence due to OAB in patients of the primary efficacy outcome variable channel-modulating effects [7]. In children, presenting with the core symptoms of urge ‘continence’ were conducted both without propiverine has been extensively investigated, incontinence and urgency. In accordance (unadjusted) and with (adjusted) especially in neurogenic [8–10], but also in with standards given meanwhile by the consideration of confounding variables. non-neurogenic conditions [11,12]. Recently, International Children’s Continence Society Thus the statistical analysis comprised as Marschall-Kehrel et al. [13] reported that in [16] a noninvasive diagnostic approach was a first-step approach the assessment of OAB, propiverine was significantly better than chosen; (ii) patients aged 5–15 years; (iii) oral noninferiority (i.e. clinical equivalence) of placebo, the first study to show the efficacy of anticholinergic treatment with either propiverine compared to oxybutynin. Only if an anticholinergic in children with this propiverine (5 mg, or of higher body weight, there was a significant result was the second- condition. Thus the aim of the present study 15 mg per coated tablet) or oxybutynin (2.5 or step approach planned of superiority (i.e. was to compare the efficacy, tolerability 5 mg tablets). Both drugs were applied as superior clinical efficacy) of propiverine and safety of propiverine and oxybutynin immediate-release formulations in variable compared to oxybutynin. These analyses had in children with urinary incontinence individual doses; (iv) treatment periods of both no adjustment for confounders. due to OAB. ≥3 months incorporating visits not scheduled but conducted according to clinical need. Key As the secondary efficacy outcome the PATIENTS AND METHODS exclusion criteria comprised: (i) children following variables were assessed according presenting with night-time symptoms only, to the data given in the patients’ files: Weekly According to Benson and Hartz [14] in a suggestive of nocturnal enuresis, were not incontinence episodes before and after retrospective cohort study, a representative eligible; (ii) children with a history of treatment; daily voiding frequency before sample of patients with the disease under recurrent chronic or acute UTI at treatment and after treatment; and overall efficacy investigation is chronologically selected from initiation; (iii) residual urine was excluded by assessment of the patients, conducted by the the population, irrespective of the applied ultrasonography; (iv) pathologies of the upper physicians (categories ‘continent’, ‘improved’, treatments and the results achieved. This urinary tract were also excluded. ‘not improved’, and ‘deteriorated’). design analyses anonymously data already Furthermore, continence rates were evaluated present before starting the study, with no This study reflects a ‘real-life’ clinical setting, in relation to the daily doses of propiverine further therapeutic interventions. Neither because the eligibility of patients was neither and oxybutynin, and for treatment duration. votes of ethics committees nor informed restricted for the prescribed doses of consent of the patients are mandatory. anticholinergics nor for concomitant As tolerability and safety variables the medication. Due to the non-interventional incidence rates of patients presenting with The present study was conducted as a character of the study, implying that the spontaneously reported adverse events (AEs), multicentre, comparative parallel-group investigators were responsible for all adverse drug reactions (ADRs) caused by observational cohort study with standardized diagnostic and therapeutic measures, patients propiverine or oxybutynin, its severity data collection, considering methods of Good were not randomly assigned to treatment grading, CNS-related ADRs and premature Epidemiologic Practice [15]. groups.
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • The Effects of Oral Administration of the Novel Muscarinic Receptor
    Choi et al. BMC Urology (2020) 20:41 https://doi.org/10.1186/s12894-020-00611-8 RESEARCH ARTICLE Open Access The effects of oral administration of the novel muscarinic receptor antagonist DA- 8010 on overactive bladder in rat with bladder outlet obstruction Jin Bong Choi1, Seung Hwan Jeon2, Eun Bi Kwon3, Woong Jin Bae4, Hyuk Jin Cho2, U-Syn Ha2, Sung-Hoo Hong2, Ji Youl Lee2 and Sae Woong Kim4* Abstract Background: DA-8010 is a novel compound developed for the treatment of overactive bladder (OAB) and urinary incontinence. The aims of this study were to investigate the effects of DA-8010 on OAB in a rat model. Methods: Study animals were divided into the following five groups of seven animals each: a sham-operated control group, a control group with partial bladder outlet obstruction (BOO) (OAB group), and three DA-8010 (doses of 0.3 mg/kg/day, 1 mg/kg/day, and 3 mg/kg/day, respectively) with partial BOO groups. Oral administration of the drugs was continued for 14 days after 2 weeks of partial BOO. After 4 weeks of partial BOO, cystometrography was performed in all groups. Additionally, pro-inflammatory cytokines, Rho-kinases, and histology of the bladder were analyzed. Results: There was a significant increase in the contraction interval and a decrease in contraction pressure in the 3 mg/kg/day DA-8010 group versus those in the OAB group. Rho kinase was also significantly decreased in the DA- 8010 3 mg/kg/day dosage treatment group. The increased ratio of collagen to smooth muscle after partial BOO was significantly attenuated in the DA-8010 3 mg/kg/day dosage group.
    [Show full text]
  • Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome
    Source of funding: Evid Based Nurs: first published as 10.1136/ebn.6.2.49 on 1 April 2003. Downloaded from Review: anticholinergic drugs improve symptoms but Health Research Council of Aotearoa increase dry mouth in adults with overactive bladder New Zealand. syndrome For correspondence: Jean Hay-Smith, Hay-Smith J, Herbison P,Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Dunedin School of Cochrane Database Syst Rev 2002;(3):CD003781 (latest version May 29 2002). Medicine, University of Otago, Dunedin, New QUESTION: What are the effects of anticholinergic drugs in adults with overactive Zealand. jean.hay-smith@ bladder syndrome? otago.ac.nz Data sources Parallel arm studies of anticholinergic drugs v placebo for overactive bladder syndrome in Studies were identified by searching the Cochrane adults at 12 days to 12 weeks* Incontinence Group trials register (to January 2002) Weighted event rates and reference lists of relevant papers. Anticholinergic Study selection Outcomes drugs Placebo RBI (95% CI) NNT (CI) Randomised or quasi-randomised controlled trials in Self reported cure or adults with symptomatic diagnosis of overactive bladder improvement (8 studies) 63% 45% 41% (29 to 54) 6 (5 to 8) syndrome, urodynamic diagnosis of detrusor overactiv- RRI (CI) NNH (CI) ity, or both, that compared an anticholinergic drug Dry mouth (20 studies) 36% 15% 138 (70 to 232) 5 (4 to 7) (given to decrease symptoms of overactive bladder) with Outcomes Weighted mean difference (CI) placebo or no treatment. Studies of darifenacin, emepronium bromide or carrageenate, dicyclomine Number of leakage episodes in 24 hours (9 − chloride, oxybutynin chloride, propiverine, propanthe- studies) 0.56 (–0.73 to –0.39) Number of micturitions in 24 hours (8 studies) −0.59 (–0.83 to –0.36) line bromide, tolterodine, and trospium chloride were Maximum cystometric volume (ml) (12 studies) 54.3 (43.0 to 65.7) included.
    [Show full text]
  • Package Leaflet
    Version 4, 02/2016 Propigen 5 mg coated tablets v005common PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER PROPIGEN 5 MG COATED TABLETS (PROPIVERINE HYDROCHLORIDE) Read all of this leaflet carefully before you or your child start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or your pharmacist. - This medicine has been prescribed for you or your child, respectively, only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours or your child’s. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet (see section 4). The name of your medicine is Propigen 5 mg. The active substance is propiverine hydrochloride and the other ingredients are listed at the end of the leaflet (section 6, Contents of the pack and other information). What is in this leaflet: 1. What Propigen 5 mg is and what it is used for 2. What you need to know before you or your child take Propigen 5 mg 3. How to take Propigen 5 mg 4. Possible side effects 5. How to store Propigen 5 mg 6. Contents of the pack and other information 1. WHAT PROPIGEN 5 MG IS AND WHAT IT IS USED FOR Propigen 5 mg is used for the treatment of adults and children who have difficulty in controlling their bladder due to bladder overactivity or, in some cases, problems with the spinal cord.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Comparision Effects of Solifenacin, Darifenacin, Propiverine on Ocular Parameters in Eyes: a Prospective Study ______
    ORIGINAL ARTICLE Vol. 46 (2): 185-193, March - April, 2020 doi: 10.1590/S1677-5538.IBJU.2019.0094 Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study _______________________________________________ Mahmut Taha Ölçücü 1, Kerem Teke 1, Kadir Yildirim 2, Mesut Toğaç 3, Burcu Işık 3, Yusuf Cem Yilmaz 3 1 Department of Urology, Agri State Hospital, Agri, Turkey; 2 Department of Urology, Elaziğ Education and Research Hospital, Elazig, Turkey; 3 Department of Ophthalmology, Agri State Hospital, Agri, Turkey ABSTRACT ARTICLE INFO Objective: To evaluate the effects of solifenacin, darifenacin, and propiverine on Mahmut Taha Ölçücü nasal-, subfoveal-, temporal choroidal thicknesses (NCT, SFCT, TCT), intraocular http://orcid.org/0000-0002-4721-2807 pressure (IOP) and pupil diameter (PD). Materials and Methods: Patients with overactive bladder (OAB) diagnosed accord- Keywords: ing to The International Continence Society were administered with solifenacin, Pressure; Urinary Bladder; darifenacin or propiverine on a daily basis between November 2017 and May 2018. Overactive; Anisocoria NCT, SFCT, TCT, IOP, and PD of these patients were measured and compared as Int Braz J Urol. 2020; 46: 185-93 initial, fourth and twelfth weeks. Results: A total of 165 patients (330 eyes) with OAB were evaluated. Solifenacin (n=140) signifi cantly reduced IOP from 17.30±2.72 mmHg to 16.67±2.56 mmHg _____________________ (p=0.006) and 16.57±2.41 mmHg (p=0.002), at the fourth and twelfth weeks, re- Submitted for publication: spectively. Darifenacin (n=110) signifi cantly reduced NCT from 258.70±23.96 μm February 08, 2019 to 257.51±22.66 μm (p=0.002) and 255.36±19.69 μm (p=0.038), at the fourth and _____________________ twelfth weeks, respectively.
    [Show full text]
  • 202 Which Anticholinergic Drug for Adults With
    202 Madhuvrata P1, Singh M2, Abdel-Fattah M3 1. Sheffield Teaching Hospital,UK, 2. Sheffield Teaching Hospital, UK, 3. University of Aberdeen, UK WHICH ANTICHOLINERGIC DRUG FOR ADULTS WITH NEUROGENIC DETRUSOR OVERACTIVITY? A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED TRIALS Hypothesis / aims of study We aim to compare the efficacy, tolerability and safety of one anticholinergic drug versus another and also higher doses of anticholinergics versus lower dose in the treatment of adult neurogenic detrusor overactivity (NDO). Study design, materials and methods : Literature search of MEDLINE, EMBASE, Cochrane incontinence specialised trials register, clinicaltrials.gov and IUGA/ICS conference abstract databases was performed from 1966 to January 2011. Randomised trials (RTs) comparing one anticholinergic drug with other or two doses of the same anticholinergic drug, in adults with NDO were included. Trials comparing anticholinergics versus placebo were excluded. Data were extracted independently by two authors. Data was analysed using Rev-Man 5. The primary outcome was the clinical cure/ improvement; both patient-reported cure and objective cure. The secondary outcomes were quality of life (Qol), Overactive bladder symptoms (urinary frequency/24hrs, urgency/24hrs, incontinence/24hrs), Urodynamic outcomes (maximum cystometric capacity, maximum detrusor contraction, number of detrusor contractions, residual volume), adverse events (dry mouth) and withdrawals due to adverse events. Fig1: Oxybutynin vs other AC- Change in frequency/24hrs
    [Show full text]
  • Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder S
    Journal of Clinical Medicine Article Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting Marjan Amiri 1,2 , Tim Schneider 3, Matthias Oelke 4, Sandra Murgas 5 and Martin C. Michel 6,* 1 Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, 45130 Essen, Germany; [email protected] 2 Center for Clinical Trials Essen (ZKSE), University Hospital Essen, 45130 Essen, Germany 3 Praxisklinik Urologie Rhein-Ruhr, 45468 Mülheim, Germany; [email protected] 4 Department of Urology, St. Antonius Hospital, 48599 Gronau, Germany; [email protected] 5 Apogepha, 01309 Dresden, Germany; [email protected] 6 Department of Pharmacology, Johannes Gutenberg University, 55131 Mainz, Germany * Correspondence: [email protected]; Tel.: +49-6131-179346 Abstract: Two doses of propiverine ER (30 and 45 mg/d) are available for the treatment of overactive bladder (OAB) syndrome. We have explored factors associated with the initial dosing choice (allo- cation bias), the decision to adapt dosing (escalation bias) and how dosing relative to other factors affects treatment outcomes. Data from two non-interventional studies of 1335 and 745 OAB patients, respectively, receiving treatment with propiverine, were analyzed post-hoc. Multivariate analysis was applied to identify factors associated with dosing decisions and treatment outcomes. Several Citation: Amiri, M.; Schneider, T.; parameters were associated with dose choice, escalation to higher dose or treatment outcomes, but Oelke, M.; Murgas, S.; Michel, M.C. only few exhibited a consistent association across both studies. These were younger age for initial Factors Associated with Decisions for dose choice and basal number of urgency and change in incontinence episodes for up-titration.
    [Show full text]
  • Pharmacological Treatment of Urinary Incontinence
    Committee 8 Pharmacological Treatment of Urinary Incontinence Chairman KARL-ERIK ANDERSSON (USA) Co-Chairman C. R CHAPPLE (U.K) Members L. CARDOZO (U.K), F. C RUZ (Portugal), H. HASHIM (U.K), M.C. MICHEL (The Netherlands), C. TANNENBAUM (Canada), A.J. WEIN (USA) 631 CONTENTS A. INTRODUCTION X. OTHER DRUGS I. PUBLICATION SEARCHES XI. COMBINATIONS II. CENTRAL NERVOUS CONTROL XII. FUTURE POSSIBILITIES III.PERIPHERALNERVOUS CONTROL C.DRUGS USED FOR IV. PATHOGENESIS OF BLADDER TREATMENT OF STRESS CONTROL DISORDERS URINARY INCONTINENCE V. BLADDER CONTRACTION I. α-ADRENCEPTOR AGONISTS VI. MUSCARINIC RECEPTORS II. β-ADRENOCEPTOR ANTAGONISTS B. DRUGS USED FOR TREATMENT OF OVERACTIVE III. β-ADRENOCEPTOR AGONISTS BLADDER SYMPTOMS/ DETRUSOR OVERACTIVITY IV. SEROTONIN-NORADRENALINE UPTAKE INHIBITORS I. ANTIMUSCARINIC (ANTICHOLINERGIC) DRUGS D.DRUGS USED FOR II. DRUGS ACTING ON MEMBRANE TREATMENT OF CHANNELS OVERFLOW INCONTINENCE III. DRUGS WITH “MIXED” ACTION E. HORMONALTREATMENT OF URINARY INCONTINENCE IV. α-ADRENOCEPTOR (AR) ANTAGONISTS I. ESTROGENS V. β-ADRENOCEPTOR AGONISTS II. OTHER STEROID HORMONE VI. PHOSPHODIESTERASE (PDE) RECEPTOR LIGANDS INHIBITORS III. DESMOPRESSIN VII. ANTIDEPRESSANTS VIII. CYCLOOXYGENASE (COX) INHIBITORS F. CONSIDERATIONS IN THE ELDERLY IX. TOXINS REFERENCES 632 Pharmacological Treatment of Urinary Incontinence KARL-ERIK ANDERSSON C. R CHAPPLE, L. CARDOZO, F. CRUZ, H. HASHIM, M.C. MICHEL, C. TANNENBAUM, A.J. WEIN Table 1. ICI assessments 2008: Oxford guidelines (modified) A. INTRODUCTION Levels of evidence Level 1: Systematic reviews, meta-analyses, good The function of the lower urinary tract (LUT) is to store quality randomized controlled clinical trials and periodically release urine, and is dependent on (RCTs) the activity of smooth and striated muscles in the Level 2: RCTs , good quality prospective cohort bladder, urethra, and pelvic floor.
    [Show full text]
  • Pharmacological Interventions for Bladder Dysfunction in Multiple Sclerosis: a Systematic Literature Review
    Pharmacological Interventions for Bladder Dysfunction In Multiple Sclerosis: A Systematic Literature Review Katelyn Sohor, B.Sc., PA-S [email protected] Supervisor: Dr. Ruth Ann Marrie A capstone project submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfillment of the requirements for the degree of MASTER OF PHYSICIAN ASSISTANT STUDIES University of Manitoba May 9, 2016 1 Abstract Background: As many as 75% of multiple sclerosis (MS) patients experience urinary symptoms during the course of their disease, which can affect many aspects of their daily life.28 Though effective pharmacological treatment for bladder dysfunction exists, effectiveness in the MS population has not been adequately reviewed. Objective: To identify, appraise, and synthesize data to determine efficacy of current pharmacological treatments for bladder dysfunction, specifically overactive bladder in patients with MS. Methods: We searched the Cochrane Database for related systemic reviews, in addition to searching the following databases for randomized controlled trials: PubMed, Medline [OVID], EMBASE [OVID], and Cochrane Central Register of Controlled Trials. Databases were searched from inception date to December 15th, 2015. We used comprehensive Cochrane review search terms for Medline, EMBASE, and the Cochrane central register. Two reviewers independently screened titles, abstracts, and full text articles to ensure all studies were randomized controlled trials, that results for MS patients were presented separately if the study had also included other patients with bladder dysfunction, and that the outcomes of interest were reported. We included studies meeting the following criteria: (1) prospective, and randomized controlled trials conducted in any setting; (2) published in English; (3) conducted on adult patients with a diagnosis of MS and experiencing bladder dysfunction, as defined by health professional or self reported symptoms; (4) Studies that examined any pharmacological therapy for treatment of bladder dysfunction in MS patients.
    [Show full text]
  • Management of Parkinson's Disease: an Evidence-Based Review
    Movement Disorders Vol. 17, Suppl. 4, 2002, p. i 2002 Movement Disorder Society Published by Wiley-Liss, Inc. DOI 10.1002/mds.5554 Editorial Management of Parkinson’s Disease: An Evidence-Based Review* Although Parkinson’s disease is still incurable, a large number tomatic control of Parkinson’s disease; prevention of motor com- of different treatments have become available to improve quality plications; control of motor complications; and control of non- of life and physical and psychological morbidity. Numerous jour- motor features. Based on a systematic review of the data, efficacy nal supplements have appeared in recent years highlighting one conclusions are provided. On the basis of a narrative non-system- or more of these and disparate treatment algorithms have prolifer- atic approach, statements on safety of the interventions are given ated. Although these are often quite useful, this “mentor analy- and finally, a qualitative approach is used to summarize the impli- sis” approach lacks the scientific rigor required by modern evi- cations for clinical practice and future research. dence-based medicine standards. The Movement Disorder Soci- This mammoth task has taken two years to complete and the ety, with generous but unrestricted support from representatives task force members, principal authors and contributors are to be of industry, have, therefore, commissioned a systematic review congratulated for their outstanding work. Physicians, the of the literature dealing with the efficacy and safety of available Parkinson’s disease research community and most of all patients treatments. The accompanying treatise is the result of a scrupu- themselves should welcome and embrace the salient findings of lous evaluation of the literature aimed at identifying those treat- this report as an effort to improve clinical practice.
    [Show full text]